



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051	The General Manager Bombay Stock Exchange Limited. Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400 001
---	--

IOLCP/CGC/2018
12 February 2018

**Sub: Press Release for Financial Results and successfully completed unit IV to
manufacture Metformin, an anti- diabetic drug**

Dear Sirs,

Please find enclosed herewith press release regarding Financial Results for the quarter and nine months ended 31 December 2017 and successfully completed unit IV to manufacture Metformin, an anti- diabetic drug for your information.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

[Krishan Singh]
Vice President & Company Secretary



For immediate release

Press Release

Impressive Results by IOL Chemicals and Pharmaceuticals Ltd

Successfully completed unit IV to manufacture Metformin, an anti- diabetic drug

Revenue from operations (QoQ) increased by 33%,

Net Profit for (QoQ) increased from ₹ 1.01 crore to ₹ 8.80 crore

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals posted an impressive performance continuously for the third quarter ended 31 December 2017.

Revenue from operations increased by 33% during the quarter ended 31 December 2017 to ₹ 262.68 crore from ₹ 197.63 crore during the corresponding quarter of the previous year.

During the nine month ended 31 December 2017 revenue from operations increased by 26% to ₹ 713.44 crore from ₹ 565.61 crore during the corresponding nine month ended 31 December 2016.

The Company has earned net profit after tax during the quarter ended 31 December 2017 of ₹ 8.80 crore against ₹ 1.01 crore during the corresponding quarter of the previous year. The operating profit for the quarter ended 31 December 2017 went up to ₹ 32.78 crore as against operating profit of ₹ 25.73 crore reported in the corresponding quarter ended 31 December 2016.

During the nine month ended 31 December 2017 the Company has earned net profit after tax of ₹ 16.21 crore against ₹ 2.67 crore during the corresponding nine month ended 31 December 2016. The operating profit for the nine month ended 31 December 2017 went up to ₹ 90.42 crore as against operating profit of ₹ 76.96 crore reported in the corresponding nine month ended 31 December 2016.

The Company has successfully started the production of Metformin, an anti-diabetes drug with an annual capacity of 3000 MT.



Mr Vijay Garg, Joint Managing Director said that *"we are pleased to inform that the Company's products are getting good response in both domestic and international market with increased share. The Company has completed the setting up of Metformin plant with a capacity of 3000 TPA from its internal accruals, which will add value to the business of the Company."*

Further, keeping in view the full capacity utilization of 7200 TPA in existing plant of Ibuprofen, we are in the process of enhancing the capacity by about 25 % through re-engineering and debottlenecking of equipment. The said enhancement is likely to be completed by the end of current financial year, which will further enhanced the turnover and profit of the Company.

The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), EDQM, WHO. The Company is already exporting its Ibuprofen to regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is one of the leading APIs company, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, Anti hypertensive, Anti Convulsants, Anti diabetes.

IOLCP's product portfolio includes APIs; Ibuprofen, Fenofibrate, Clopidogrel, Metformin and Lamotrigine and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid and Acetyl Chloride.

Company is one of the largest producer of the Ibuprofen with an installed capacity of 7200TPA and having complete backward integrated manufacturing facility at one location. The company has DSIR approved R&D which is fully equipped to validate existing processes.

backward integrated

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance.

IOLCP's overseas customers are spread out across several countries including Brazil, Argentina, Austria, Hungary, USA, Spain, Switzerland Chile, China, Peru, Colombia, South Korea, Thailand, Iran and many other Middle East Countries. Products are sold primarily to Branded Generic formulators both in India & Overseas.

